Pan-KRas Inhibitor Compounds for Mutation Coverage and Resistance Bypass
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRas inhibitors have not demonstrated sufficient safety and efficacy to obtain regulatory approval for treating KRas-mediated cancers, particularly those with KRas mutations such as G12C, G12D, G12R, G12S, G12V, G13D, and Q61H, and there is a need for pan-KRas inhibitors that can overcome resistance mechanisms in cancers treated with existing KRas G12C inhibitors.
Innovation Solution
Development of compounds represented by Formula (I) that inhibit KRas activity, including wild type and multiple mutated forms, such as G12A, G12C, G12D, G12R, G12S, G12V, G13D, and Q61H, through specific structural modifications that allow for broad-spectrum inhibition and resistance bypass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing KRas G12C inhibitors are used to treat cancers, then specific KRas G12C mutations are inhibited, but resistance mechanisms develop and other KRas mutations remain unaffected
Solution Approach 1:
The compound of Formula (I) is designed to inhibit multiple KRas mutation types (G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, and wild type KRas) through a single molecular structure. The compound achieves pan-KRas inhibition by targeting conserved regions of the KRas protein that are common across all mutation types, thereby providing universal coverage without requiring multiple different inhibitors.
Solution Approach 2:
The patent employs specific structural modifications in Formula (I) including varying the substituent R1 (C1-C3 alkyl or hydroxy), adjusting the ring structure (saturated or unsaturated), and modifying the linker chain length (n=1-4) to optimize binding affinity across different KRas mutations. These parameter changes enable the compound to maintain effective inhibition across diverse mutation types while overcoming resistance mechanisms.
2Adaptability or versatility
If KRas inhibitors are developed to target multiple mutations, then broader cancer coverage is achieved, but compound complexity increases
Solution Approach 1:
The compound of Formula (I) introduces specific functional groups at localized positions (R1 substituent on the ring, X and Y atoms in the heterocyclic system, Z atom in the linker) to achieve broad KRas mutation coverage. By concentrating the diversity-generating elements at specific local positions rather than throughout the entire molecule, the patent maintains relative structural simplicity while achieving pan-KRas inhibition.
Data Source
AI summary
The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.